Home
Live Updates
CHMP Recommends Frontline Nivolumab Plus Chemo in Unresectable/Metastatic Urothelial Carcinoma : comparemela.com
CHMP Recommends Frontline Nivolumab Plus Chemo in Unresectable/Metastatic Urothelial Carcinoma
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Related Keywords
Dana Walker ,
Bristol Myers Squibb Opdivo ,
European Commission ,
European Union ,
Bristol Myers Squibb ,
European Medicines Agency ,
Medicinal Products ,
Human Use ,
New England Journal ,
Genitourinary Cancers ,
comparemela.com © 2020. All Rights Reserved.